Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2025-06-11 Earnings Release
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
Earnings Release Classification · 95% confidence The document is a press release dated June 11, 2025, announcing positive Phase 2 proof-of-concept results for the drug efgartigimod in Myositis (ALKIVIA study) and Sjogren's Disease (RHO study) presented at the EULAR 2025 congress. It details clinical endpoints, safety profiles, study designs (ALKIVIA and RHO), and provides background on the diseases and the drug. This content structure—announcing clinical data presentation and providing detailed results—is characteristic of an Earnings Release (ER) or a specific clinical data announcement. Since it focuses heavily on the clinical trial results and their significance rather than just the quarterly financial figures, it is best classified as an Earnings Release (ER) which often includes key operational/clinical updates, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release detailing results, ER is the closest fit among the options for a major operational/clinical update. However, upon reviewing the definitions, 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is purely clinical data presentation highlights, not financial results highlights. The document is a detailed announcement of clinical trial data presented at a conference. This type of announcement, which is a significant update on product development and clinical progress, often falls under general Regulatory Filings (RNS) if no other category fits perfectly. Given the options, it is not a 10-K, AR, CT, or IR. It is not a formal Investor Presentation (IP) format, nor is it a simple Report Publication Announcement (RPA). Since it is a detailed announcement of clinical progress and data presentation, and it is not a standard financial report, 'RNS' (Regulatory Filings / General regulatory announcements) serves as the most appropriate fallback for a significant, non-financial, non-meeting-related corporate update. Revisiting the options: It is a major corporate update about clinical progress. If the company had an earnings call, this data might be discussed, but the document itself is the press release announcing the data. Given the lack of a specific 'Clinical Data Release' code, RNS is the best fit as a general regulatory/corporate announcement. Q2 2025
2025-06-11 English
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a short announcement (1558 characters) regarding a company executive's participation in an upcoming investor conference. It provides details on the event, date, and how to access the webcast, but it is not the presentation itself. Since it serves as an announcement of an upcoming investor event/presentation, it falls under the general regulatory announcement category as it does not fit into specific report types like 10-K or IR.
2025-06-03 English
argenx Announces Results of Annual General Meeting of Shareholders
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'argenx Announces Results of Annual General Meeting of Shareholders'. It explicitly details the voting outcomes for various agenda items, including the percentage of share capital represented and the specific approval rates for resolutions such as the remuneration report, annual accounts, and director re-appointments. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2025-05-29 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, argenx SE, with the SEC. It references an attached press release (Exhibit 99.1) dated May 28, 2025. The document itself is short (2099 characters) and primarily serves as a cover report to incorporate the press release by reference. There is no substantive financial data or detailed report content within this filing. According to the MENU VS MEAL RULE, such a short document that announces or attaches another report (here, a press release) should be classified as a Regulatory Filing (RNS) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-05-28 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, argenx SE, with the SEC. It references a press release and an investor presentation attached as exhibits. The document itself is a current report providing updates and attaching other materials, not a full financial report or detailed analysis. The length is short (2103 characters), and it mainly announces the filing and incorporation of other documents. According to the rules, such a document is a Regulatory Filing (RNS) as it does not contain substantive financial data or detailed report content but serves as a regulatory announcement and filing notice.
2025-05-08 English
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
Earnings Release Classification · 100% confidence The document is a press release titled 'argenx Reports First Quarter 2025 Financial Results and Provides Business Update'. It contains key financial highlights, a summary of business operations, and unaudited condensed consolidated interim financial statements for the three-month period ended March 31, 2025. As it is an initial announcement of quarterly financial results rather than a full interim report or a mere announcement of a report's publication, it fits the definition of an Earnings Release (ER). Q1 2025
2025-05-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.